Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs United States Copper Index Fund (CPER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs United States Copper Index Fund — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.07 (market cap $29.60B), while United States Copper Index Fund trades at $40.12. The key difference: United States Copper Index Fund is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CPER | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $491.22 | $40.85 |
52-Week Low | $205.48 | $27.57 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
CPER (United States Copper Index Fund) trades at $40.115, down 0.16% on the day, with a bullish technical signal driven by moving averages. The copper market faces supply constraints from Chilean weather disruptions and strong AI/electrification demand, pushing prices to record highs. Recent news highlights copper's structural bull case amid global infrastructure investment and supply chain pressures.
Outlook remains positive given copper's fundamental supply-demand imbalance, though risks include potential substitution to aluminum and geopolitical tensions. The ETF provides pure copper exposure without mining operational risks, appealing for investors betting on continued electrification trends and AI infrastructure growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →
